Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Analysts gave Protara a consensus recommendation of “Moderate Buy” (1 sell, 4 buy, 1 strong buy) with an average 12‑month price target of $23.75, while the stock trades near about $5.13.
• Insider Jacqueline Zummo sold 22,598 shares at an average $5.26 on April 1, reducing her stake by 19.06%; insiders collectively own 8.40% of the company.
• Protara reported an EPS loss of ($0.37) for the quarter (missing the ($0.34) estimate), analysts expect roughly –1.58 EPS for the fiscal year, and the company has a market cap of about $282.5M with a 52‑week range of $2.77–$7.82.

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $23.75.

Several brokerages have commented on TARA. HC Wainwright restated a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a research report on Tuesday, February 10th. TD Cowen reaffirmed a "buy" rating on shares of Protara Therapeutics in a research note on Tuesday, March 10th. JPMorgan Chase & Co. started coverage on shares of Protara Therapeutics in a research note on Wednesday, March 4th. They set an "overweight" rating and a $27.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Protara Therapeutics in a research note on Tuesday. Finally, Piper Sandler started coverage on shares of Protara Therapeutics in a research note on Wednesday, January 7th. They set an "overweight" rating and a $24.00 target price on the stock.

Insider Buying and Selling at Protara Therapeutics

In other Protara Therapeutics news, insider Jacqueline Zummo sold 22,598 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total transaction of $118,865.48. Following the sale, the insider owned 95,961 shares of the company's stock, valued at approximately $504,754.86. The trade was a 19.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 8.40% of the company's stock.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers grew its stake in shares of Protara Therapeutics by 8.2% during the third quarter. Rhumbline Advisers now owns 34,137 shares of the company's stock worth $148,000 after buying an additional 2,596 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Protara Therapeutics by 26.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,736 shares of the company's stock worth $111,000 after buying an additional 4,383 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of Protara Therapeutics by 35.8% during the third quarter. Two Sigma Investments LP now owns 19,558 shares of the company's stock worth $85,000 after buying an additional 5,154 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Protara Therapeutics by 7.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 102,499 shares of the company's stock worth $546,000 after buying an additional 6,725 shares during the last quarter. Finally, Quadrature Capital Ltd grew its stake in shares of Protara Therapeutics by 39.4% during the fourth quarter. Quadrature Capital Ltd now owns 24,184 shares of the company's stock worth $129,000 after buying an additional 6,838 shares during the last quarter. Institutional investors own 38.13% of the company's stock.

Protara Therapeutics Price Performance

Shares of TARA opened at $5.13 on Friday. Protara Therapeutics has a one year low of $2.77 and a one year high of $7.82. The company has a market cap of $282.46 million, a P/E ratio of -3.89 and a beta of 1.50. The firm has a 50 day simple moving average of $5.56 and a two-hundred day simple moving average of $5.71.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, analysts expect that Protara Therapeutics will post -1.58 earnings per share for the current fiscal year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company's primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body's immune response to target tumor cells. Protara's therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara's lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.